Last updated: February 24, 2026
What is NDC 00228-2348?
NDC 00228-2348 is the National Drug Code for Prolia (denosumab), a monoclonal antibody indicated for osteoporosis treatment, bone loss prevention in cancer patients, and related conditions.
Market Size and Growth
Market Overview:
- The global osteoporosis drugs market was valued at approximately $13 billion in 2022.
- The U.S. osteoporosis market accounted for roughly 45% of this, representing about $5.85 billion.
- The market is projected to grow at a compound annual growth rate (CAGR) of 4.8% through 2030.
Market Drivers:
- Aging population increases osteoporosis incidence.
- Growing awareness and diagnosis.
- Expanded labeled uses for conditions like bone metastases.
- High treatment adherence rates due to Prolia's dosing schedule.
Market Segments:
| Segment |
Market Share (2022) |
CAGR (2022-2030) |
| Osteoporosis in postmenopausal women |
65% |
4.5% |
| Bone metastases in cancer |
25% |
5.2% |
| Other indications |
10% |
4.0% |
Competitive Landscape
Major Players:
- Amgen (Prolia, Xgeva)
- UCB (Evenity)
- Eli Lilly (Taltz; indirect competition for osteoporosis)
Market Share by Drug (2022):
| Drug |
Share |
Sales (USD millions) |
| Prolia |
80% |
$3.2 billion |
| Xgeva |
15% |
$600 million |
| Other |
5% |
$200 million |
Pricing Benchmarks:
- U.S. average wholesale price (AWP): Approximately $2,100 per 60 mg dose.
- Administration: Subcutaneous injection every six months.
Price Projections (2023–2030)
Current Price:
- Per-dose wholesale price approximately $2,100.
- Estimated annual cost per patient: around $4,200 (assuming two doses annually).
Factors Influencing Price Changes:
- Patent status and biosimilar entry.
- Reimbursement and insurance coverage policies.
- Manufacturing costs and supply chain considerations.
Projected Price Trends:
| Year |
Estimated Wholesale Price per Dose |
Key Influences |
| 2023 |
$2,100 |
Current market, no biosimilar competition |
| 2025 |
$2,050 |
Slight downward pressure from biosimilar entry in 2024-2025 |
| 2027 |
$1,950 |
Increased biosimilar competition and cost savings |
| 2030 |
$1,850 |
Mature biosimilar market, price stabilization |
Biosimilar Entry Timeline:
- First biosimilar applications filed in the U.S. in 2024.
- Anticipated market entry by 2025-2026.
- Biosimilar price discounts projected at 20–30% relative to originator prices.
Regulatory and Policy Impact
- Biosimilars approved by FDA: Labeled as "interchangeable," influencing pricing.
- CMS and private insurers' policies favor biosimilar adoption, exerting downward pressure on branded drug prices.
- Patent litigation delays may affect biosimilar market entry timelines.
Revenue Projections
| Year |
Estimated U.S. Market Revenue (USD billions) |
Assumptions |
| 2023 |
$3.2 |
Based on 80% market share of Prolia |
| 2025 |
$3.0 |
Slight market share decline as biosimilars enter |
| 2030 |
$2.7 |
Market consolidation and biosimilar competition |
Key Takeaways
- The overall market for denosumab (NDC 00228-2348) remains robust, driven by aging demographics and expanding indications.
- Prices are expected to decline gradually due to biosimilar competition, with a potential 15-20% decrease by 2025-2027.
- Revenue in the U.S. is projected to remain stable at approximately $3 billion annually through 2025, then slightly decline as biosimilars penetrate.
- The biosimilar pipeline's launch timeline will significantly influence future pricing and market share.
FAQs
1. When do biosimilars for Prolia enter the market?
Biosimilar applications were filed starting in 2024, with market entry anticipated between 2025 and 2026, depending on patent litigation outcomes.
2. How will biosimilar competition affect Prolia's price?
Biosimilars may reduce prices by 20-30%, leading to lower treatment costs but potentially reduced revenues for the originator.
3. What are the main drivers of market growth for denosumab?
The primary drivers are increasing osteoporosis prevalence, expanding indications, and higher treatment adherence.
4. How does insurance coverage impact price projections?
Insurance policies favor biosimilar adoption, resulting in negotiated discounts and influencing overall pricing trends.
5. What regulatory factors could shift the market?
Patent disputes, FDA approvals of biosimilars, and policy incentives for biosimilar use will shape the market landscape.
References
[1] MarketWatch. (2023). Osteoporosis drugs market size, shares, growth & trends.
[2] Evaluate Pharma. (2022). Biosimilar landscape and forecast.
[3] U.S. Food and Drug Administration. (2022). Biosimilar approval list.
[4] IQVIA. (2023). U.S. pharmaceutical trends report.
[5] Amgen Inc. Annual Report. (2022).
